Lastly, the limited evidence on the effects of GLP-1 RAs on key pathognomonic proteins, Aβ and α-synuclein, weakens the scientific basis for considering GLP-1 RAs as major game-changers for neurodegenerative diseases. The gene discussed is GLP1R; the disease is neurodegenerative disease.